Rheumatoid Arthritis - Pipeline Review, H1 2017

Published: Jun, 2017 | Pages: 1020 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rheumatoid Arthritis - Pipeline Review, H1 2017, provides an overview of the Rheumatoid Arthritis (Immunology) pipeline landscape.

Rheumatoid arthritis (RA) is an autoimmune chronic disorder that eventually leads to destruction of bones causing deformities. Signs and symptoms of rheumatoid arthritis include tender, warm, swollen joints, fatigue, and fever and weight loss. Rheumatoid arthritis may be a result of genetic and certain specific environmental factors. Women are much more susceptible to develop RA. Treatment includes non-steroidal anti-inflammatory drugs, corticosteroid medications and immunosuppressants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rheumatoid Arthritis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Rheumatoid Arthritis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rheumatoid Arthritis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Rheumatoid Arthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 17, 27, 48, 62, 7, 223, 52 and 7 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 2, 37 and 12 molecules, respectively.

Rheumatoid Arthritis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Rheumatoid Arthritis (Immunology).
- The pipeline guide reviews pipeline therapeutics for Rheumatoid Arthritis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Rheumatoid Arthritis (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Rheumatoid Arthritis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Rheumatoid Arthritis (Immunology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Rheumatoid Arthritis (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Rheumatoid Arthritis (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
Introduction 10
Rheumatoid Arthritis - Overview 11
Rheumatoid Arthritis - Therapeutics Development 12
Rheumatoid Arthritis - Therapeutics Assessment 60
Rheumatoid Arthritis - Companies Involved in Therapeutics Development 82
Rheumatoid Arthritis - Drug Profiles 194
Rheumatoid Arthritis - Dormant Projects 919
Rheumatoid Arthritis - Discontinued Products 948
Rheumatoid Arthritis - Product Development Milestones 955
Appendix 972

List of Tables

Number of Products under Development for Rheumatoid Arthritis, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..9), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..10), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..11), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..12), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..13), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..14), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Products under Development by Companies, H1 2017 (Contd..5), H1 2017
Products under Development by Companies, H1 2017 (Contd..6), H1 2017
Products under Development by Companies, H1 2017 (Contd..7), H1 2017
Products under Development by Companies, H1 2017 (Contd..8), H1 2017
Products under Development by Companies, H1 2017 (Contd..9), H1 2017
Products under Development by Companies, H1 2017 (Contd..10), H1 2017
Products under Development by Companies, H1 2017 (Contd..11), H1 2017
Products under Development by Companies, H1 2017 (Contd..12), H1 2017
Products under Development by Companies, H1 2017 (Contd..13), H1 2017
Products under Development by Companies, H1 2017 (Contd..14), H1 2017
Products under Development by Companies, H1 2017 (Contd..15), H1 2017
Products under Development by Companies, H1 2017 (Contd..16), H1 2017
Products under Development by Companies, H1 2017 (Contd..17), H1 2017
Products under Development by Companies, H1 2017 (Contd..18), H1 2017
Products under Development by Companies, H1 2017 (Contd..19), H1 2017
Products under Development by Companies, H1 2017 (Contd..20), H1 2017
Products under Development by Companies, H1 2017 (Contd..21), H1 2017
Products under Development by Companies, H1 2017 (Contd..22), H1 2017
Products under Development by Companies, H1 2017 (Contd..23), H1 2017
Products under Development by Universities/Institutes, H1 2017
Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..6), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..7), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..6), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..7), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Rheumatoid Arthritis - Pipeline by 3SBio Inc, H1 2017
Rheumatoid Arthritis - Pipeline by 4D Pharma PLC, H1 2017
Rheumatoid Arthritis - Pipeline by AB Science SA, H1 2017
Rheumatoid Arthritis - Pipeline by AbbVie Inc, H1 2017
Rheumatoid Arthritis - Pipeline by Ablynx NV, H1 2017
Rheumatoid Arthritis - Pipeline by ACEA Biosciences Inc, H1 2017
Rheumatoid Arthritis - Pipeline by Addex Therapeutics Ltd, H1 2017
Rheumatoid Arthritis - Pipeline by Adello Biologics LLC, H1 2017
Rheumatoid Arthritis - Pipeline by Advinus Therapeutics Ltd, H1 2017
Rheumatoid Arthritis - Pipeline by Allergan Plc, H1 2017
Rheumatoid Arthritis - Pipeline by Alteogen Inc, H1 2017
Rheumatoid Arthritis - Pipeline by Alvotech Iceland, H1 2017
Rheumatoid Arthritis - Pipeline by Amarna Therapeutics BV, H1 2017
Rheumatoid Arthritis - Pipeline by Amgen Inc, H1 2017
Rheumatoid Arthritis - Pipeline by Amura Holdings Ltd, H1 2017
Rheumatoid Arthritis - Pipeline by AnGes MG Inc, H1 2017
Rheumatoid Arthritis - Pipeline by Applied Genetic Technologies Corp, H1 2017
Rheumatoid Arthritis - Pipeline by Aptevo Therapeutics Inc, H1 2017
Rheumatoid Arthritis - Pipeline by ARA Healthcare Pvt Ltd, H1 2017
Rheumatoid Arthritis - Pipeline by Arrien Pharmaceuticals LLC, H1 2017
Rheumatoid Arthritis - Pipeline by Arthrogen BV, H1 2017
Rheumatoid Arthritis - Pipeline by Asahi Kasei Pharma Corp, H1 2017
Rheumatoid Arthritis - Pipeline by Asana BioSciences LLC, H1 2017
Rheumatoid Arthritis - Pipeline by Astellas Pharma Inc, H1 2017
Rheumatoid Arthritis - Pipeline by AstraZeneca Plc, H1 2017
Rheumatoid Arthritis - Pipeline by Atlantic Bio Sci LLC, H1 2017
Rheumatoid Arthritis - Pipeline by Aurigene Discovery Technologies Ltd, H1 2017
Rheumatoid Arthritis - Pipeline by Axxam SpA, H1 2017
Rheumatoid Arthritis - Pipeline by BCN Peptides SA, H1 2017
Rheumatoid Arthritis - Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H1 2017
Rheumatoid Arthritis - Pipeline by Bio-Cancer Treatment International Ltd, H1 2017
Rheumatoid Arthritis - Pipeline by Biocad, H1 2017
Rheumatoid Arthritis - Pipeline by Biocon Ltd, H1 2017
Rheumatoid Arthritis - Pipeline by BioLingus AG, H1 2017
Rheumatoid Arthritis - Pipeline by BioLite Inc, H1 2017
Rheumatoid Arthritis - Pipeline by Bionovis SA, H1 2017
Rheumatoid Arthritis - Pipeline by Biozeus, H1 2017
Rheumatoid Arthritis - Pipeline by Bird Rock Bio Inc, H1 2017
Rheumatoid Arthritis - Pipeline by Boehringer Ingelheim GmbH, H1 2017
Rheumatoid Arthritis - Pipeline by Bristol-Myers Squibb Company, H1 2017
Rheumatoid Arthritis - Pipeline by Can-Fite BioPharma Ltd, H1 2017
Rheumatoid Arthritis - Pipeline by Cardax Inc, H1 2017
Rheumatoid Arthritis - Pipeline by CASI Pharmaceuticals Inc, H1 2017
Rheumatoid Arthritis - Pipeline by CEL-SCI Corp, H1 2017
Rheumatoid Arthritis - Pipeline by Celgene Corp, H1 2017
Rheumatoid Arthritis - Pipeline by Celltrion Inc, H1 2017
Rheumatoid Arthritis - Pipeline by ChemoCentryx Inc, H1 2017
Rheumatoid Arthritis - Pipeline by Chipscreen Biosciences Ltd, H1 2017
Rheumatoid Arthritis - Pipeline by ChironWells GmbH, H1 2017
Rheumatoid Arthritis - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2017
Rheumatoid Arthritis - Pipeline by CJ HealthCare Corp, H1 2017
Rheumatoid Arthritis - Pipeline by Clevexel Pharma SAS, H1 2017
Rheumatoid Arthritis - Pipeline by CLL Pharma SA, H1 2017
Rheumatoid Arthritis - Pipeline by Coherus BioSciences Inc, H1 2017
Rheumatoid Arthritis - Pipeline by Commence Bio Inc, H1 2017
Rheumatoid Arthritis - Pipeline by Compugen Ltd, H1 2017
Rheumatoid Arthritis - Pipeline by Confluence Life Sciences Inc, H1 2017
Rheumatoid Arthritis - Pipeline by Crossject SA, H1 2017
Rheumatoid Arthritis - Pipeline by CSL Ltd, H1 2017
Rheumatoid Arthritis - Pipeline by Cyclacel Pharmaceuticals Inc, H1 2017
Rheumatoid Arthritis - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017
Rheumatoid Arthritis - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
Rheumatoid Arthritis - Pipeline by Diamyd Medical AB, H1 2017
Rheumatoid Arthritis - Pipeline by Domainex Ltd, H1 2017
Rheumatoid Arthritis - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2017
Rheumatoid Arthritis - Pipeline by Dr. Reddy's Laboratories Ltd, H1 2017
Rheumatoid Arthritis - Pipeline by Eisai Co Ltd, H1 2017
Rheumatoid Arthritis - Pipeline by Eli Lilly and Company, H1 2017
Rheumatoid Arthritis - Pipeline by Enceladus Pharmaceuticals BV, H1 2017
Rheumatoid Arthritis - Pipeline by Endocyte Inc, H1 2017
Rheumatoid Arthritis - Pipeline by Enzene Biosciences Ltd, H1 2017
Rheumatoid Arthritis - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Rheumatoid Arthritis - Pipeline by Fountain Biopharma Inc, H1 2017
Rheumatoid Arthritis - Pipeline by Galapagos NV, H1 2017
Rheumatoid Arthritis - Pipeline by Gene Techno Science Co Ltd, H1 2017
Rheumatoid Arthritis - Pipeline by Genentech Inc, H1 2017
Rheumatoid Arthritis - Pipeline by Genfit SA, H1 2017
Rheumatoid Arthritis - Pipeline by Genor BioPharma Co Ltd, H1 2017
Rheumatoid Arthritis - Pipeline by Genosco Inc, H1 2017
Rheumatoid Arthritis - Pipeline by Gilead Sciences Inc, H1 2017
Rheumatoid Arthritis - Pipeline by GlaxoSmithKline Plc, H1 2017
Rheumatoid Arthritis - Pipeline by Griffin Discoveries BV, H1 2017
Rheumatoid Arthritis - Pipeline by Han Wha Pharma Co Ltd, H1 2017
Rheumatoid Arthritis - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017
Rheumatoid Arthritis - Pipeline by Hansa Medical AB, H1 2017
Rheumatoid Arthritis - Pipeline by Hanwha Chemical Corp, H1 2017
Rheumatoid Arthritis - Pipeline by Hetero Drugs Ltd, H1 2017
Rheumatoid Arthritis - Pipeline by HitGen LTD, H1 2017
Rheumatoid Arthritis - Pipeline by Huabo Biopharm Co Ltd, H1 2017
Rheumatoid Arthritis - Pipeline by Humabs BioMed SA, H1 2017
Rheumatoid Arthritis - Pipeline by Hutchison China MediTech Ltd, H1 2017
Rheumatoid Arthritis - Pipeline by Idogen AB, H1 2017
Rheumatoid Arthritis - Pipeline by Immune Response BioPharma Inc, H1 2017
Rheumatoid Arthritis - Pipeline by Immune Therapeutics Inc, H1 2017
Rheumatoid Arthritis - Pipeline by Immungenetics AG, H1 2017
Rheumatoid Arthritis - Pipeline by ImmunoFrontier Inc, H1 2017
Rheumatoid Arthritis - Pipeline by Immunwork Inc, H1 2017
Rheumatoid Arthritis - Pipeline by Immupharma Plc, H1 2017
Rheumatoid Arthritis - Pipeline by Innate Pharma SA, H1 2017
Rheumatoid Arthritis - Pipeline by Innovent Biologics Inc, H1 2017
Rheumatoid Arthritis - Pipeline by Intas Pharmaceuticals Ltd, H1 2017
Rheumatoid Arthritis - Pipeline by Japan Tobacco Inc, H1 2017
Rheumatoid Arthritis - Pipeline by JHL Biotech Inc, H1 2017
Rheumatoid Arthritis - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017
Rheumatoid Arthritis - Pipeline by Johnson & Johnson, H1 2017
Rheumatoid Arthritis - Pipeline by Jyant Technologies Inc, H1 2017
Rheumatoid Arthritis - Pipeline by Kadmon Corp LLC, H1 2017
Rheumatoid Arthritis - Pipeline by KAHR medical Ltd, H1 2017
Rheumatoid Arthritis - Pipeline by Kang Stem Biotech Co Ltd, H1 2017
Rheumatoid Arthritis - Pipeline by Karyopharm Therapeutics Inc, H1 2017
Rheumatoid Arthritis - Pipeline by KPI Therapeutics Inc, H1 2017
Rheumatoid Arthritis - Pipeline by Lead Pharma Holding BV, H1 2017
Rheumatoid Arthritis - Pipeline by Lexicon Pharmaceuticals Inc, H1 2017
Rheumatoid Arthritis - Pipeline by LG Chem, Ltd., H1 2017
Rheumatoid Arthritis - Pipeline by Lipocure Ltd, H1 2017
Rheumatoid Arthritis - Pipeline by Livzon Pharmaceutical Group Inc, H1 2017
Rheumatoid Arthritis - Pipeline by LSK BioPartners Inc, H1 2017
Rheumatoid Arthritis - Pipeline by Lupin Ltd, H1 2017
Rheumatoid Arthritis - Pipeline by Mabion SA, H1 2017
Rheumatoid Arthritis - Pipeline by mAbxience SA, H1 2017
Rheumatoid Arthritis - Pipeline by MacroGenics Inc, H1 2017
Rheumatoid Arthritis - Pipeline by Mebiopharm Co Ltd, H1 2017
Rheumatoid Arthritis - Pipeline by MedAnnex Ltd, H1 2017
Rheumatoid Arthritis - Pipeline by Medestea Research & Production SpA, H1 2017
Rheumatoid Arthritis - Pipeline by MediGene AG, H1 2017
Rheumatoid Arthritis - Pipeline by MedImmune LLC, H1 2017
Rheumatoid Arthritis - Pipeline by Merck & Co Inc, H1 2017
Rheumatoid Arthritis - Pipeline by Merck KGaA, H1 2017
Rheumatoid Arthritis - Pipeline by Mesoblast Ltd, H1 2017
Rheumatoid Arthritis - Pipeline by Millennium Pharmaceuticals Inc, H1 2017
Rheumatoid Arthritis - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2017
Rheumatoid Arthritis - Pipeline by Modern Biosciences Plc, H1 2017
Rheumatoid Arthritis - Pipeline by ModiQuest Group, H1 2017
Rheumatoid Arthritis - Pipeline by Momenta Pharmaceuticals Inc, H1 2017
Rheumatoid Arthritis - Pipeline by Morphotek Inc, H1 2017
Rheumatoid Arthritis - Pipeline by Mycenax Biotech Inc, H1 2017
Rheumatoid Arthritis - Pipeline by MYOS RENS Technology Inc, H1 2017
Rheumatoid Arthritis - Pipeline by Myungmoon pharmaceutical Co Ltd, H1 2017
Rheumatoid Arthritis - Pipeline by NanoSmart Pharmaceuticals Inc, H1 2017
Rheumatoid Arthritis - Pipeline by Nissan Chemical Industries Ltd, H1 2017
Rheumatoid Arthritis - Pipeline by Novartis AG, H1 2017
Rheumatoid Arthritis - Pipeline by NovelMed Therapeutics Inc, H1 2017
Rheumatoid Arthritis - Pipeline by NovImmune SA, H1 2017
Rheumatoid Arthritis - Pipeline by Novo Nordisk A/S, H1 2017
Rheumatoid Arthritis - Pipeline by Nuevolution AB, H1 2017
Rheumatoid Arthritis - Pipeline by Numab Innovation AG, H1 2017
Rheumatoid Arthritis - Pipeline by Omeros Corp, H1 2017
Rheumatoid Arthritis - Pipeline by Oncobiologics Inc, H1 2017
Rheumatoid Arthritis - Pipeline by Oncodesign SA, H1 2017
Rheumatoid Arthritis - Pipeline by OncoImmune Inc, H1 2017
Rheumatoid Arthritis - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017
Rheumatoid Arthritis - Pipeline by Opsona Therapeutics Ltd, H1 2017
Rheumatoid Arthritis - Pipeline by OSE Immunotherapeutics, H1 2017
Rheumatoid Arthritis - Pipeline by Panacea Biotec Ltd, H1 2017
Rheumatoid Arthritis - Pipeline by Paras Biopharmaceuticals Finland Oy, H1 2017
Rheumatoid Arthritis - Pipeline by Peptinov SAS, H1 2017
Rheumatoid Arthritis - Pipeline by Pfenex Inc, H1 2017
Rheumatoid Arthritis - Pipeline by Pfizer Inc, H1 2017
Rheumatoid Arthritis - Pipeline by Pharmacyclics Inc, H1 2017
Rheumatoid Arthritis - Pipeline by Pharmedartis GmbH, H1 2017
Rheumatoid Arthritis - Pipeline by Philogen SpA, H1 2017
Rheumatoid Arthritis - Pipeline by PLx Pharma Inc, H1 2017
Rheumatoid Arthritis - Pipeline by Principia Biopharma Inc, H1 2017
Rheumatoid Arthritis - Pipeline by ProNoxis AB, H1 2017
Rheumatoid Arthritis - Pipeline by Protab Ltd, H1 2017
Rheumatoid Arthritis - Pipeline by Protalex Inc, H1 2017
Rheumatoid Arthritis - Pipeline by Protalix BioTherapeutics Inc, H1 2017
Rheumatoid Arthritis - Pipeline by Qilu Pharmaceutical Co Ltd, H1 2017
Rheumatoid Arthritis - Pipeline by Qu Biologics Inc, H1 2017
Rheumatoid Arthritis - Pipeline by R Pharm, H1 2017
Rheumatoid Arthritis - Pipeline by ReceptoPharm Inc, H1 2017
Rheumatoid Arthritis - Pipeline by RedHill Biopharma Ltd, H1 2017
Rheumatoid Arthritis - Pipeline by Redx Pharma Plc, H1 2017
Rheumatoid Arthritis - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017
Rheumatoid Arthritis - Pipeline by Reliance Life Sciences Pvt Ltd, H1 2017
Rheumatoid Arthritis - Pipeline by Resverlogix Corp, H1 2017
Rheumatoid Arthritis - Pipeline by ReveraGen BioPharma Inc, H1 2017
Rheumatoid Arthritis - Pipeline by Rhizen Pharmaceuticals SA, H1 2017
Rheumatoid Arthritis - Pipeline by Ribomic Inc, H1 2017
Rheumatoid Arthritis - Pipeline by Richter Gedeon Nyrt, H1 2017
Rheumatoid Arthritis - Pipeline by Rottapharm Biotech Srl, H1 2017
Rheumatoid Arthritis - Pipeline by Saje Pharma LLC, H1 2017
Rheumatoid Arthritis - Pipeline by Sandoz International GmbH, H1 2017
Rheumatoid Arthritis - Pipeline by Sareum Holdings Plc, H1 2017
Rheumatoid Arthritis - Pipeline by SBI Biotech Co Ltd, H1 2017
Rheumatoid Arthritis - Pipeline by Selecta Biosciences Inc, H1 2017
Rheumatoid Arthritis - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H1 2017
Rheumatoid Arthritis - Pipeline by Shanghai Pharmaceutical Co Ltd, H1 2017
Rheumatoid Arthritis - Pipeline by Spherium Biomed SL, H1 2017
Rheumatoid Arthritis - Pipeline by Synovo GmbH, H1 2017
Rheumatoid Arthritis - Pipeline by Syntrix Biosystems Inc, H1 2017
Rheumatoid Arthritis - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
Rheumatoid Arthritis - Pipeline by Teijin Pharma Ltd, H1 2017
Rheumatoid Arthritis - Pipeline by TheraMAB LLC, H1 2017
Rheumatoid Arthritis - Pipeline by Tiziana Life Sciences Plc, H1 2017
Rheumatoid Arthritis - Pipeline by Toleranzia AB, H1 2017
Rheumatoid Arthritis - Pipeline by Tumorend LLC, H1 2017
Rheumatoid Arthritis - Pipeline by TxCell SA, H1 2017
Rheumatoid Arthritis - Pipeline by U.S. Stem Cell Inc, H1 2017
Rheumatoid Arthritis - Pipeline by UCB SA, H1 2017
Rheumatoid Arthritis - Pipeline by United BioPharma Inc, H1 2017
Rheumatoid Arthritis - Pipeline by Vaccinex Inc, H1 2017
Rheumatoid Arthritis - Pipeline by Valeant Pharmaceuticals International Inc, H1 2017
Rheumatoid Arthritis - Pipeline by VentiRx Pharmaceuticals Inc, H1 2017
Rheumatoid Arthritis - Pipeline by Vicore Pharma AB, H1 2017
Rheumatoid Arthritis - Pipeline by viDA Therapeutics Inc, H1 2017
Rheumatoid Arthritis - Pipeline by Xbrane Biopharma AB, H1 2017
Rheumatoid Arthritis - Pipeline by Xencor Inc, H1 2017
Rheumatoid Arthritis - Pipeline by XL-protein GmbH, H1 2017
Rheumatoid Arthritis - Pipeline by Yungjin Pharm Co Ltd, H1 2017
Rheumatoid Arthritis - Pipeline by Yuyu Pharma Inc, H1 2017
Rheumatoid Arthritis - Pipeline by Zenyaku Kogyo Co Ltd, H1 2017
Rheumatoid Arthritis - Pipeline by Zydus Cadila Healthcare Ltd, H1 2017
Rheumatoid Arthritis - Dormant Projects, H1 2017
Rheumatoid Arthritis - Dormant Projects, H1 2017 (Contd..1), H1 2017
Rheumatoid Arthritis - Dormant Projects, H1 2017 (Contd..2), H1 2017
Rheumatoid Arthritis - Dormant Projects, H1 2017 (Contd..3), H1 2017
Rheumatoid Arthritis - Dormant Projects, H1 2017 (Contd..4), H1 2017
Rheumatoid Arthritis - Dormant Projects, H1 2017 (Contd..5), H1 2017
Rheumatoid Arthritis - Dormant Projects, H1 2017 (Contd..6), H1 2017
Rheumatoid Arthritis - Dormant Projects, H1 2017 (Contd..7), H1 2017
Rheumatoid Arthritis - Dormant Projects, H1 2017 (Contd..8), H1 2017
Rheumatoid Arthritis - Dormant Projects, H1 2017 (Contd..9), H1 2017
Rheumatoid Arthritis - Dormant Projects, H1 2017 (Contd..10), H1 2017
Rheumatoid Arthritis - Dormant Projects, H1 2017 (Contd..11), H1 2017
Rheumatoid Arthritis - Dormant Projects, H1 2017 (Contd..12), H1 2017
Rheumatoid Arthritis - Dormant Projects, H1 2017 (Contd..13), H1 2017
Rheumatoid Arthritis - Dormant Projects, H1 2017 (Contd..14), H1 2017
Rheumatoid Arthritis - Dormant Projects, H1 2017 (Contd..15), H1 2017
Rheumatoid Arthritis - Dormant Projects, H1 2017 (Contd..16), H1 2017
Rheumatoid Arthritis - Dormant Projects, H1 2017 (Contd..17), H1 2017
Rheumatoid Arthritis - Dormant Projects, H1 2017 (Contd..18), H1 2017
Rheumatoid Arthritis - Dormant Projects, H1 2017 (Contd..19), H1 2017
Rheumatoid Arthritis - Dormant Projects, H1 2017 (Contd..20), H1 2017
Rheumatoid Arthritis - Dormant Projects, H1 2017 (Contd..21), H1 2017
Rheumatoid Arthritis - Dormant Projects, H1 2017 (Contd..22), H1 2017
Rheumatoid Arthritis - Dormant Projects, H1 2017 (Contd..23), H1 2017
Rheumatoid Arthritis - Dormant Projects, H1 2017 (Contd..24), H1 2017
Rheumatoid Arthritis - Dormant Projects, H1 2017 (Contd..25), H1 2017
Rheumatoid Arthritis - Dormant Projects, H1 2017 (Contd..26), H1 2017
Rheumatoid Arthritis - Dormant Projects, H1 2017 (Contd..27), H1 2017
Rheumatoid Arthritis - Discontinued Products, H1 2017
Rheumatoid Arthritis - Discontinued Products, H1 2017 (Contd..1), H1 2017
Rheumatoid Arthritis - Discontinued Products, H1 2017 (Contd..2), H1 2017
Rheumatoid Arthritis - Discontinued Products, H1 2017 (Contd..3), H1 2017
Rheumatoid Arthritis - Discontinued Products, H1 2017 (Contd..4), H1 2017
Rheumatoid Arthritis - Discontinued Products, H1 2017 (Contd..5), H1 2017
Rheumatoid Arthritis - Discontinued Products, H1 2017 (Contd..6), H1 2017